

=> dis his

(FILE 'HOME' ENTERED AT 15:31:39 ON 29 FEB 2004)

FILE 'MEDLINE, CAPLUS, BIOSIS, BIOTECHDS, EMBASE, USPATFULL, WPIDS'
ENTERED AT 15:31:58 ON 29 FEB 2004

L1 28602 S (ALPHA-1-ACID GLYCOPROTEIN OR AAG OR OROSMUCOID OR ACUTE PLAS
L2 3371 S L1 AND (LIPOPOLYSACCHARIDE OR LPS OR ENDOTOXIN#)
L3 3076 S L2 AND (REMOV? OR PURIF? OR PREPAR? OR DEPYROGEN?)
L4 2076 S L3 AND (RESIN OR SILICA-BASED OR FUMED SILICA OR HYDROPHIL?)
L5 2062 S L4 AND (VIR? INACTIVAT? OR TREAT? OR DISINFECT?)
L6 1521 S L5 AND (REMOV? ENDOTOXIN OR LIPOPOLYSACCHARIDE OR LPS)
L7 1446 S L6 AND (ANION EXCHANGE MATRIX OR CHROMATOG?)
L8 4 S L7 AND (ANION EXCHANGE MATRIX)
L9 1446 S L7 AND (DEPYROGENAT? OR INACTIVAT? OR TREAT?)
L10 5 S L9 AND (COHN FRACTION?)
L11 5 DUP REM L10 (0 DUPLICATES REMOVED)
L12 1057 S L9 AND (FILTRAT? OR PASTEURIZ?)
L13 781 S L12 AND (RESIN)
L14 780 S REMOV? AND L13
L15 22 S DEPYROGEN? AND L14
L16 2 S L8 AND L15
L17 2 S L10 AND L15
L18 2 S L16 AND L17
L19 2 S L16 AND (DRUG TOXIC?)

=> dup rem l15

PROCESSING COMPLETED FOR L15

L20 22 DUP REM L15 (0 DUPLICATES REMOVED)

=> s l20 and (medica? or therap?)

6 FILES SEARCHED...

L21 22 L20 AND (MEDICA? OR THERAP?)

=> s l21 and (0.050 Eu/mg or 01. Eu/mg or 0.075 Eu/mg)

'MG' IS NOT A VALID FIELD CODE

L22 0 L21 AND (0.050 EU/MG OR 01. EU/MG OR 0.075 EU/MG)

=> s l21 and (concentrat?)

L23 22 L21 AND (CONCENTRAT?)

=> s l23 and (0.1 or 0.075 or 0.050)

6 FILES SEARCHED...

L24 22 L23 AND (0.1 OR 0.075 OR 0.050)

=> s l24 and (virus deplet? or virus inactivat?)

L25 2 L24 AND (VIRUS DEPLET? OR VIRUS INACTIVAT?)

=> d l25 1-2 bib ab

L25 ANSWER 1 OF 2 USPATFULL on STN

AN 2002:235983 USPATFULL

TI Purification method

IN More, John Edward, Elstree, UNITED KINGDOM

Rott, Jacqueline, Elstree, UNITED KINGDOM

Lewin, David Roger, Elstree, UNITED KINGDOM

PA National Blood Authority (non-U.S. corporation)

PI US 2002128180 A1 20020912

AI US 2002-82925 A1 20020226 (10)
RLI Continuation of Ser. No. US 1999-142348, filed on 25 Jan 1999, PENDING A
371 of International Ser. No. WO 1997-GB642, filed on 7 Mar 1997,
UNKNOWN
PRAI GB 1996-4921 19960308
DT Utility
FS APPLICATION
LREP SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A., P.O. BOX 2938, MINNEAPOLIS,
MN, 55402
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 971
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to a method of removing
endotoxin from preparation of alpha-
1-acid glycoprotein (orosomucoid) by contact
with a finely divided non-toxic resin such as fumed
silica. The invention also relates to a purification
process for alpha-1-acid
glycoprotein which includes this depyrogenation step,
and to the depyrogenated product and its clinical uses.

L25 ANSWER 2 OF 2 USPATFULL on STN
AN 2002:109017 USPATFULL
TI Purification method
IN More, John Edward, Elstree, UNITED KINGDOM
Rott, Jacqueline, Elstree, UNITED KINGDOM
Lewin, David Roger, Elstree, UNITED KINGDOM
PA National Blood Authority, UNITED KINGDOM (non-U.S. corporation)
PI US 6387877 B1 20020514
WO 9732893 19970912
AI US 1999-142348 19990125 (9)
WO 1997-GB642 19970307
19990125 PCT 371 date

PRAI DE 1996-4921 19960308
DT Utility
FS GRANTED
EXNAM Primary Examiner: Low, Christopher S. F.; Assistant Examiner: Mohamed,
Abdel A.
LREP Schwegman, Lundberg, Woessner & Kluth, P.A.
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 942

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to a method of removing
endotoxin from preparations of alpha-
1-acid glycoprotein (orosomucoid) by contact
with a finely divided non-toxic resin such as fumed
silica. The invention also relates to a purification
process for alpha-1-acid
glycoprotein which includes this depyrogenation step, and to the
depyrogenated product and its clinical uses.

=> d 124 1-5 bib ab

L24 ANSWER 1 OF 22 USPATFULL on STN
AN 2003:311862 USPATFULL
TI Soluble recombinant botulinum toxins
IN Williams, James A., Madison, WI, UNITED STATES
PA Allergan Sales, Inc., Allergan Botox Limited, Irvine, CA, UNITED STATES,
92612 (U.S. corporation)
PI US 2003219457 A1 20031127

AI US 2002-271012 A1 20021015 (10)
RLI Continuation of Ser. No. US 1996-704159, filed on 28 Aug 1996, PENDING
Continuation-in-part of Ser. No. US 1995-405496, filed on 16 Mar 1995,
GRANTED, Pat. No. US 5919665
DT Utility
FS APPLICATION
LREP STOUT, UXA, BUYAN & MULLINS LLP, 4 VENTURE, SUITE 300, IRVINE, CA, 92618
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 40 Drawing Page(s)
LN.CNT 16361

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A, type B and type E toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant **endotoxin** contamination are provided. The soluble, **endotoxin-free** recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the **treatment** of humans and other animals at risk of intoxication with clostridial toxin.

L24 ANSWER 2 OF 22 USPATFULL on STN
AN 2003:306036 USPATFULL
TI Soluble recombinant botulinum toxin proteins
IN Williams, James A., Madison, WI, UNITED STATES
Thalley, Bruce S., Madison, WI, UNITED STATES
PA Allergan, Inc., Allergan Botox Limited, Irvine, CA, 92612 (U.S.
corporation)
PI US 2003215468 A1 20031120
AI US 2003-354774 A1 20030130 (10)
RLI Continuation of Ser. No. US 1996-704159, filed on 28 Aug 1996, PENDING
Continuation-in-part of Ser. No. US 1995-405496, filed on 16 Mar 1995,
GRANTED, Pat. No. US 5919665
DT Utility
FS APPLICATION
LREP STOUT, UXA, BUYAN & MULLINS LLP, 4 VENTURE, SUITE 300, IRVINE, CA, 92618
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 40 Drawing Page(s)
LN.CNT 16347

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A, type B and type E toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant **endotoxin** contamination are provided. The soluble, **endotoxin-free** recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the **treatment** of humans and other animals at risk of intoxication with clostridial toxin.

L24 ANSWER 3 OF 22 USPATFULL on STN
AN 2003:299854 USPATFULL
TI Combined compositions for tumor vasculature coagulation and
treatment
IN Thorpe, Philip E., Dallas, TX, UNITED STATES
King, Steven W., Rancho Santa Margarita, CA, UNITED STATES
Gottstein, Claudia, Dallas, TX, UNITED STATES
PI US 2003211075 A1 20031113
AI US 2002-259244 A1 20020927 (10)
PRAI US 2001-325532P 20010927 (60)
DT Utility
FS APPLICATION
LREP Shelley P.M. Fussey, Ph.D., Williams, Morgan & Amerson, P.C., Suite

1100, 10333 Richmond Avenue, Houston, TX, 77042
CLMN Number of Claims: 43
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 9999
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are various defined combinations of agents for use in improved anti-vascular **therapies** and coagulative tumor **treatment**. Particularly provided are combined **treatment** methods, and associated compositions, pharmaceuticals, **medicaments**, kits and uses, which together function surprisingly effectively in the **treatment** of vascularized tumors. The invention preferably involves a component or **treatment** step that enhances the effectiveness of **therapy** using targeted or non-targeted coagulants to cause tumor vasculature thrombosis.

L24 ANSWER 4 OF 22 USPATFULL on STN
AN 2003:257253 USPATFULL
TI Lipopolysaccharide binding protein derivatives
IN Gazzano-Santoro, Helene, San Bruno, CA, UNITED STATES
Theofan, Georgia, Torrance, CA, UNITED STATES
Trown, Patrick, Danville, CA, UNITED STATES
PA XOMA Technology Ltd., Berkeley, CA (U.S. corporation)
PI US 2003180303 A1 20030925
AI US 2002-131686 A1 20020423 (10)
RLI Continuation of Ser. No. US 1999-280909, filed on 29 Mar 1999, GRANTED, Pat. No. US 6376462 Continuation of Ser. No. US 1997-985446, filed on 5 Dec 1997, ABANDONED Continuation of Ser. No. US 1994-261660, filed on 17 Jun 1994, GRANTED, Pat. No. US 5731415 Continuation-in-part of Ser. No. US 1993-79510, filed on 17 Jun 1993, ABANDONED
DT Utility
FS APPLICATION
LREP MARSHALL, GERSTEIN & BORUN, 6300 SEARS TOWER, 233 SOUTH WACKER, CHICAGO, IL, 60606-6357
CLMN Number of Claims: 32
ECL Exemplary Claim: 1
DRWN 21 Drawing Page(s)
LN.CNT 2591
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are novel biologically active **lipopolysaccharide** binding protein (LBP) derivatives including LBP derivative hybrid proteins which are characterized by the ability to bind to and neutralize **LPS** and which lack the CD14-mediated immunostimulatory properties of holo-LBP.

L24 ANSWER 5 OF 22 USPATFULL on STN
AN 2003:234579 USPATFULL
TI Vaccine and antitoxin for **treatment** and prevention of C. difficile disease
IN Kink, John A., Madison, WI, United States
Williams, James A., Lincoln, NE, United States
PA Promega Corporation, Madison, WI, United States (U.S. corporation)
PI US 6613329 B1 20030902
AI US 1998-84517 19980526 (9)
RLI Continuation of Ser. No. US 1995-422711, filed on 14 Apr 1995, now abandoned Continuation-in-part of Ser. No. US 1995-405496, filed on 16 Mar 1995, now patented, Pat. No. US 5919665 Continuation-in-part of Ser. No. US 1994-329154, filed on 24 Oct 1994, now abandoned Continuation-in-part of Ser. No. US 1993-161907, filed on 2 Dec 1993, now patented, Pat. No. US 5601823 Continuation-in-part of Ser. No. US 1992-985321, filed on 4 Dec 1992 Continuation-in-part of Ser. No. US 1989-429791, filed on 31 Oct 1989, now patented, Pat. No. US 5196193
DT Utility
FS GRANTED
EXNAM Primary Examiner: Kunz, Gary; Assistant Examiner: Turner, Sharon

LREP Medlen & Carroll, LLP
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 48 Drawing Figure(s); 46 Drawing Page(s)
LN.CNT 11913

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present provides neutralizing antitoxin directed against *C. difficile* toxins. These antitoxins are produced in avian species using soluble recombinant *C. difficile* toxin proteins. The avian antitoxins are designed so as to be orally administrable in **therapeutic** amounts and may be in any form (i.e., as a solid or in aqueous solution). Solid forms of the antitoxin may comprise an enteric coating. These antitoxins are useful in the **treatment** of humans and other animals intoxicated with at least one bacterial toxin. The invention further provides vaccines capable of protecting a vaccinated recipient from the morbidity and mortality associated with *C. difficile* infection. These vaccines are useful for administration to humans and other animals at risk of exposure to *C. difficile* toxins.

=> d 124 10-20 bib ab

L24 ANSWER 10 OF 22 USPATFULL on STN
AN 2003:53682 USPATFULL
TI Immune responses against HPV antigens elicited by compositions comprising an HPV antigen and a stress protein or an expression vector capable of expression of these proteins
IN Mizzen, Lee A., Victoria, CANADA
Chu, N. Randall, Victoria, CANADA
Wu, Huacheng Bill, Victoria, CANADA
PA Stressgen Biotechnologies, Inc., Vancouver, CANADA (non-U.S. corporation)
PI US 6524825 B1 20030225
AI US 2000-498918 20000204 (9)
RLI Continuation of Ser. No. WO 1998-CA246, filed on 20 Mar 1998
PRAI US 1997-54835P 19970805 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Park, Hankyel T.
LREP Fish & Richardson P.C.
CLMN Number of Claims: 100
ECL Exemplary Claim: 1
DRWN 13 Drawing Figure(s); 13 Drawing Page(s)
LN.CNT 2285

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compositions for inducing an immune response, preferably a cellular, in particular a cell-mediated, cytolytic immune response, to human papillomavirus (HPV) protein antigens displayed by HPV or exhibited by infected cells including cells from cervical and other tumors. In one embodiment, compositions comprise an HPV protein antigen joined to a stress protein (or heat shock protein (Hsp)). The HPV protein antigen may be joined to the stress protein by chemical conjugation or noncovalently using linking moieties, or the HPV protein antigen and the stress protein may be joined in a fusion protein containing both HPV protein antigen and stress protein sequences. In another embodiment, compositions comprise an expression vector including, in expressible form, sequences encoding the HPV protein antigen and sequences encoding the stress protein. The expression vector can be introduced into cells of a subject, or it can be used to transduce cells of the subject *ex vivo*, resulting in the expression of an HPV protein antigen-stress protein fusion protein that will stimulate the subject's immune response to the HPV protein antigen. The present invention also relates to compositions comprising a stress protein linked to an HPV antigen and another pharmacologically acceptable component, to stress protein-HPV protein antigen fusions and conjugates

and to expression vectors encoding and capable of directing the expression in a subject's cells of a fusion protein comprising a stress protein and an HPV protein antigen sequence. The present invention also relates to uses of these compositions to induce immune responses against HPV and HPV protein antigen-exhibiting cells including HPV-associated tumors.

L24 ANSWER 11 OF 22 USPATFULL on STN
AN 2002:235983 USPATFULL
TI **Purification** method
IN More, John Edward, Elstree, UNITED KINGDOM
Rott, Jacqueline, Elstree, UNITED KINGDOM
Lewin, David Roger, Elstree, UNITED KINGDOM
PA National Blood Authority (non-U.S. corporation)
PI US 2002128180 A1 20020912
AI US 2002-82925 A1 20020226 (10)
RLI Continuation of Ser. No. US 1999-142348, filed on 25 Jan 1999, PENDING A
371 of International Ser. No. WO 1997-GB642, filed on 7 Mar 1997,
UNKNOWN
PRAI GB 1996-4921 19960308
DT Utility
FS APPLICATION
LREP SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A., P.O. BOX 2938, MINNEAPOLIS,
MN, 55402
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 971
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to a method of **removing**
endotoxin from **preparation** of **alpha-**
1-acid glycoprotein (orosomucoid) by contact
with a finely divided non-toxic **resin** such as **fumed**
silica. The invention also relates to a **purification**
process for **alpha-1-acid**
glycoprotein which includes this **depyrogenation** step,
and to the **depyrogenated** product and its clinical uses.

L24 ANSWER 12 OF 22 USPATFULL on STN
AN 2002:221788 USPATFULL
TI Uses of **lipopolysaccharide** binding protein
IN Dedrick, Russell L., Kensington, CA, UNITED STATES
Carroll, Stephen F., Walnut Creek, CA, UNITED STATES
PA XOMA Corporation (U.S. corporation)
PI US 2002119930 A1 20020829
US 2003236187 A9 20031225
AI US 2001-4139 A1 20011023 (10)
RLI Continuation of Ser. No. US 1999-395453, filed on 14 Sep 1999, GRANTED,
Pat. No. US 6306824
DT Utility
FS APPLICATION
LREP HONEYWELL INTERNATIONAL INC., 101 COLUMBIA ROAD, P O BOX 2245,
MORRISTOWN, NJ, 07962-2245
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 977
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel LBP compositions and **therapeutic** uses for LBP are
provided for preventing the adverse effects of exposure to
endotoxin.

L24 ANSWER 13 OF 22 USPATFULL on STN
AN 2002:109017 USPATFULL
TI **Purification** method

IN More, John Edward, Elstree, UNITED KINGDOM
Rott, Jacqueline, Elstree, UNITED KINGDOM
Lewin, David Roger, Elstree, UNITED KINGDOM
PA National Blood Authority, UNITED KINGDOM (non-U.S. corporation)
PI US 6387877 B1 20020514
WO 9732893 19970912
AI US 1999-142348 19990125 (9)
WO 1997-GB642 19970307
19990125 PCT 371 date
PRAI DE 1996-4921 19960308
DT Utility
FS GRANTED
EXNAM Primary Examiner: Low, Christopher S. F.; Assistant Examiner: Mohamed, Abdel A.
LREP Schwegman, Lundberg, Woessner & Kluth, P.A.
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 942
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to a method of removing endotoxin from preparations of alpha-1-acid glycoprotein (orosomucoid) by contact with a finely divided non-toxic resin such as fumed silica. The invention also relates to a purification process for alpha-1-acid glycoprotein which includes this deprogenation step, and to the depyrogenated product and its clinical uses.

L24 ANSWER 14 OF 22 USPATFULL on STN
AN 2002:102619 USPATFULL
TI Endotoxin binding and neutralizing protein and uses thereof
IN Wainwright, Norman R., Falmouth, MA, United States
Novitsky, Thomas J., E. Falmouth, MA, United States
PA Associates of Cape Cod, Inc., Falmouth, MA, United States (U.S. corporation)
PI US 6384200 B1 20020507
AI US 1997-850011 19970501 (8)
RLI Division of Ser. No. US 1995-476940, filed on 7 Jun 1995, now patented, Pat. No. US 5627266, issued on 6 May 1997 Division of Ser. No. US 1994-264244, filed on 22 Jun 1994, now patented, Pat. No. US 5594113, issued on 14 Jan 1997 Continuation of Ser. No. US 1992-883457, filed on 15 May 1992, now abandoned Continuation-in-part of Ser. No. US 1991-701501, filed on 16 May 1991, now abandoned Continuation-in-part of Ser. No. US 1990-480957, filed on 16 Feb 1990, now abandoned Division of Ser. No. US 1988-210575, filed on 23 Jun 1988, now abandoned

DT Utility
FS GRANTED
EXNAM Primary Examiner: Tsang, Cecilia J.; Assistant Examiner: Gupta, Anish
LREP Sterne, Kessler, Goldstein & Fox P.L.L.C.

CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 16 Drawing Figure(s); 16 Drawing Page(s)
LN.CNT 1219

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Endotoxin binding/neutralizing proteins capable of binding endotoxin in vivo, thereby neutralizing the toxic effect or bioactivity of endotoxin which are isolated from a horseshoe crab such as Limulus polyphemus, pharmaceutical compositions and pharmaceutical uses of the proteins, a method of purifying the proteins and an assay for endotoxin based on the proteins, are disclosed.

L24 ANSWER 15 OF 22 USPATFULL on STN
AN 2002:88454 USPATFULL

TI Lipopolysaccharide binding protein derivatives
IN Gazzano-Santoro, Hele{overscore (n)}e, San Bruno, CA, United States
Theofan, Georgia, Torrance, CA, United States
Trown, Patrick W., Danville, CA, United States
PA Xoma Corporation, Berkeley, CA, United States (U.S. corporation)
PI US 6376462 B1 20020423
AI US 1999-280909 19990329 (9)
RLI Continuation of Ser. No. US 1997-985446, filed on 5 Dec 1997, now
abandoned Continuation of Ser. No. US 1994-261660, filed on 17 Jun 1994,
now patented, Pat. No. US 5731415 Continuation-in-part of Ser. No. US
1993-79510, filed on 17 Jun 1993, now abandoned

DT Utility
FS GRANTED

EXNAM Primary Examiner: Romeo, David S.

LREP Marshall, Gerstein, & Borun

CLMN Number of Claims: 15

ECL Exemplary Claim: 1

DRWN 26 Drawing Figure(s); 25 Drawing Page(s)

LN.CNT 2606

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are novel biologically active lipopolysaccharide binding protein (LBP) derivatives including LBP derivative hybrid proteins which are characterized by the ability to bind to and neutralize LPS and which lack the CD14-mediated immunostimulatory properties of holo-LBP.

L24 ANSWER 16 OF 22 USPATFULL on STN

AN 2002:21823 USPATFULL

TI PREVENTION AND TREATMENT OF VEROTOXIN-INDUCED DISEASE

IN WILLIAMS, JAMES A., LINCOLN, NE, UNITED STATES

BYRNE, LISA MARIE, STOUGHTON, WI, UNITED STATES

PUGH, CHARLES S.G., MADISON, WI, UNITED STATES

PI US 2002012658 A1 20020131

US 6652857 B2 20031125

AI US 1999-334477 A1 19990616 (9)

RLI Continuation of Ser. No. US 1997-816977, filed on 13 Mar 1997, GRANTED,
Pat. No. US 6080400

DT Utility

FS APPLICATION

LREP KAMRIN T MACKNIGHT, MEDLEN & CARROLL LLP, 220 MONTGOMERY STREET, SUITE
2200, SAN FRANCISCO, CA, 94104

CLMN Number of Claims: 51

ECL Exemplary Claim: 1

DRWN 18 Drawing Page(s)

LN.CNT 5803

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention includes methods for generating neutralizing antitoxin directed against verotoxins. In preferred embodiments, the antitoxin directed against these toxins is produced in avian species using soluble recombinant verotoxin proteins. This antitoxin is designed so as to be administrable in therapeutic amounts and may be in any form (i.e., as a solid or in aqueous solution). These antitoxins are useful in the treatment of humans and other animals intoxicated with at least one bacterial toxin, as well as for preventive treatment, and diagnostic assays to detect the presence of toxin in a sample.

L24 ANSWER 17 OF 22 USPATFULL on STN

AN 2000:80408 USPATFULL

TI Compositions for the prevention and treatment of verotoxin-induced disease

IN Williams, James A., Lincoln, NE, United States

Byrne, Lisa Marie, Stoughton, WI, United States

PA Ophidian Pharmaceuticals, Inc., Wisconsin, United States (U.S.
corporation)

PI US 6080400 20000627
AI US 1997-816977 19970313 (8)
RLI Continuation-in-part of Ser. No. US 1995-410058, filed on 24 Mar 1995,
now abandoned

DT Utility
FS Granted

EXNAM Primary Examiner: Housel, James C.; Assistant Examiner: Devi, S.

LREP Medlen & Carroll, LLP

CLMN Number of Claims: 2

ECL Exemplary Claim: 1

DRWN 1 Drawing Figure(s); 9 Drawing Page(s)

LN.CNT 5468

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention includes methods for generating neutralizing antitoxin directed against verotoxins. In preferred embodiments, the antitoxin directed against these toxins is produced in avian species using soluble recombinant verotoxin proteins. This antitoxin is designed so as to be administrable in **therapeutic** amounts and may be in any form (i.e., as a solid or in aqueous solution). These antitoxins are useful in the **treatment** of humans and other animals intoxicated with at least one bacterial toxin, as well as for preventive **treatment**, and diagnostic assays to detect the presence of toxin in a sample.

L24 ANSWER 18 OF 22 USPATFULL on STN

AN 1999:151185 USPATFULL

TI Uses of **lipopolysaccharide** binding protein

IN Dedrick, Russell L., Kensington, CA, United States

Carroll, Stephen F., Walnut Creek, CA, United States

PA Xoma Corporation, Berkeley, CA, United States (U.S. corporation)

PI US 5990082 19991123

AI US 1997-955660 19971022 (8)

DT Utility

FS Granted

EXNAM Primary Examiner: Tsang, Cecilia J.; Assistant Examiner: Borin, Michael

LREP Marshall, O'Toole, Gerstein, Murray & Borun

CLMN Number of Claims: 3

ECL Exemplary Claim: 1

DRWN 7 Drawing Figure(s); 7 Drawing Page(s)

LN.CNT 1136

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel LBP compositions and **therapeutic** uses for LBP are provided for preventing the adverse effects of exposure to **endotoxin**.

L24 ANSWER 19 OF 22 USPATFULL on STN

AN 1999:75522 USPATFULL

TI Vaccine for **clostridium** botulinum neurotoxin

IN Williams, James A., Madison, WI, United States

PA Ophidian Pharmaceuticals, Inc., Madison, WI, United States (U.S. corporation)

PI US 5919665 19990706

AI US 1995-405496 19950316 (8)

RLI Continuation-in-part of Ser. No. US 1994-329154, filed on 25 Oct 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-161907, filed on 2 Dec 1993, now patented, Pat. No. US 5601823 which is a continuation-in-part of Ser. No. US 1992-985321, filed on 4 Dec 1992 which is a continuation-in-part of Ser. No. US 1989-429791, filed on 31 Oct 1989, now patented, Pat. No. US 5196193, issued on 23 Mar 1993

DT Utility

FS Granted

EXNAM Primary Examiner: Eisenschenk, Frank C.; Assistant Examiner: Rabin, Evelyn

LREP Medlen & Carroll, LLP

CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 31 Drawing Figure(s); 29 Drawing Page(s)
LN.CNT 9164

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant endotoxin contamination are provided. The soluble, endotoxin-free recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the treatment of humans and other animals at risk of intoxication with clostridial toxin.

L24 ANSWER 20 OF 22 USPATFULL on STN
AN 1998:159467 USPATFULL
TI Methods of inhibiting complement activation
IN Ko, Jone-Long, Sudbury, MA, United States
Higgins, Paul J., Medford, MA, United States
Yeh, C. Grade, Marlborough, MA, United States
PA Cytomed, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 5851528 19981222
AI US 1997-888171 19970703 (8)
RLI Division of Ser. No. US 1994-310416, filed on 22 Sep 1994, now patented, Pat. No. US 5679546 which is a continuation-in-part of Ser. No. US 1993-126596, filed on 24 Sep 1993, now abandoned

DT Utility
FS Granted
EXNAM Primary Examiner: Kemmerer, Elizabeth C.; Assistant Examiner: Romeo, David S.

LREP Fish & Richardson P.C.
CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN 15 Drawing Figure(s); 10 Drawing Page(s)
LN.CNT 1744

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel chimeric proteins comprising a first polypeptide which inhibits complement activation, linked to a second polypeptide which inhibits complement activation, nucleic acids encoding novel chimeric proteins and methods of reducing inflammation with the administration of the chimeric proteins of the invention.

=> d 124 6-9 bib ab

L24 ANSWER 6 OF 22 USPATFULL on STN
AN 2003:213818 USPATFULL
TI Immune responses against HPV antigens elicited by compositions comprising an HPV antigen and a stress protein or an expression vector capable of expression of these proteins
IN Mizzen, Lee A., Victoria, CANADA
Chu, N. Randall, Victoria, CANADA
Wu, Huacheng Bill, Victoria, CANADA
PA Stressgen Biotechnologies, Inc., a British Columbia, Canada corporation (non-U.S. corporation)
PI US 2003148456 A1 20030807
AI US 2002-289760 A1 20021107 (10)
RLI Continuation of Ser. No. US 2000-498918, filed on 4 Feb 2000, GRANTED, Pat. No. US 6524825 Continuation of Ser. No. WO 1998-CA246, filed on 20 Mar 1998, UNKNOWN
PRAI US 1997-54835P 19970805 (60)
DT Utility
FS APPLICATION
LREP LEE CREWS, PH.D., Fish & Richardson P.C., 225 Franklin Street, Boston,

MA, 02110-2804
CLMN Number of Claims: 44
ECL Exemplary Claim: 1
DRWN 13 Drawing Page(s)
LN.CNT 1784

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compositions for inducing an immune response, preferably a cellular, in particular a cell-mediated, cytolytic immune response, to human papillomavirus (HPV) protein antigens displayed by HPV or exhibited by infected cells including cells from cervical and other tumors. In one embodiment, compositions comprise an HPV protein antigen joined to a stress protein (or heat shock protein (Hsp)). The HPV protein antigen may be joined to the stress protein by chemical conjugation or noncovalently using linking moieties, or the HPV protein antigen and the stress protein may be joined in a fusion protein containing both HPV protein antigen and stress protein sequences. In another embodiment, compositions comprise an expression vector including, in expressible form, sequences encoding the HPV protein antigen and sequences encoding the stress protein. The expression vector can be introduced into cells of a subject, or it can be used to transduce cells of the subject ex vivo, resulting in the expression of an HPV protein antigen-stress protein fusion protein that will stimulate the subject's immune response to the HPV protein antigen. The present invention also relates to compositions comprising a stress protein linked to an HPV antigen and another pharmacologically acceptable component, to stress protein-HPV protein antigen fusions and conjugates and to expression vectors encoding and capable of directing the expression in a subject's cells of a fusion protein comprising a stress protein and an HPV protein antigen sequence. The present invention also relates to uses of these compositions to induce immune responses against HPV and HPV protein antigen-exhibiting cells including HPV-associated tumors.

L24 ANSWER 7 OF 22 USPATFULL ON STN
AN 2003:201388 USPATFULL
TI Combined methods for tumor vasculature coagulation and treatment
IN Thorpe, Philip E., Dallas, TX, UNITED STATES
King, Steven W., Rancho Santa Margarita, CA, UNITED STATES
Gottstein, Claudia, Dallas, TX, UNITED STATES
PA Board of Regents, The University of Texas System and Peregrine
Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003139374 A1 20030724
AI US 2002-259236 A1 20020927 (10)
PRAI US 2001-325532P 20010927 (60)
DT Utility
FS APPLICATION
LREP Shelley P.M. Fussey, Williams, Morgan & Amerson, P.C., Suite 250, 7676
Hillmont, Houston, TX, 77040
CLMN Number of Claims: 43
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 10003

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are various defined combinations of agents for use in improved anti-vascular **therapies** and coagulative tumor **treatment**. Particularly provided are combined **treatment** methods, and associated compositions, pharmaceuticals, **medicaments**, kits and uses, which together function surprisingly effectively in the **treatment** of vascularized tumors. The invention preferably involves a component or **treatment** step that enhances the effectiveness of **therapy** using targeted or non-targeted coagulants to cause tumor vasculature thrombosis.

L24 ANSWER 8 OF 22 USPATFULL ON STN
AN 2003:187407 USPATFULL

TI Combined methods for tumor vasculature coaguligand **treatment**
IN Thorpe, Philip E., Dallas, TX, UNITED STATES
King, Steven W., Rancho Santa Margarita, CA, UNITED STATES
Gottstein, Claudia, Dallas, TX, UNITED STATES
PA Board of Regents, The University of Texas System and Peregrine
Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003129193 A1 20030710
AI US 2002-259227 A1 20020927 (10)
PRAI US 2001-325532P 20010927 (60)
DT Utility
FS APPLICATION
LREP Shelley P.M. Fussey, Williams, Morgan & Amerson, P.C., Suite 250, 7676
Hillmont, Houston, TX, 77040
CLMN Number of Claims: 45
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 10012
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are various defined combinations of agents for use in improved
anti-vascular **therapies** and coagulative tumor
treatment. Particularly provided are combined **treatment**
methods, and associated compositions, pharmaceuticals,
medicaments, kits and uses, which together function surprisingly
effectively in the **treatment** of vascularized tumors. The
invention preferably involves a component or **treatment** step
that enhances the effectiveness of **therapy** using targeted or
non-targeted coagulants to cause tumor vasculature thrombosis.

L24 ANSWER 9 OF 22 USPATFULL on STN
AN 2003:180305 USPATFULL
TI Combined compositions for tumor vasculature coaguligand
treatment
IN Thorpe, Philip E., Dallas, TX, UNITED STATES
King, Steven W., Rancho Santa Margarita, CA, UNITED STATES
Gottstein, Claudia, Dallas, TX, UNITED STATES
PA Board of Regents, The University of Texas System (U.S. corporation)
PI US 2003124132 A1 20030703
AI US 2002-259223 A1 20020927 (10)
PRAI US 2001-325532P 20010927 (60)
DT Utility
FS APPLICATION
LREP Shelley P.M. Fussey, Ph.D., WILLIAMS, MORGAN & AMERSON, P.C., Suite
1100, 10333 Richmond Avenue, Houston, TX, 77042
CLMN Number of Claims: 45
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 10025

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are various defined combinations of agents for use in improved
anti-vascular **therapies** and coagulative tumor
treatment. Particularly provided are combined **treatment**
methods, and associated compositions, pharmaceuticals,
medicaments, kits and uses, which together function surprisingly
effectively in the **treatment** of vascularized tumors. The
invention preferably involves a component or **treatment** step
that enhances the effectiveness of **therapy** using targeted or
non-targeted coagulants to cause tumor vasculature thrombosis.

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

STN INTERNATIONAL LOGOFF AT 16:10:46 ON 29 FEB 2004